<DOC>
	<DOCNO>NCT02502500</DOCNO>
	<brief_summary>To assess single dose pharmacokinetics ( PK ) celecoxib healthy subject administer alone follow multiple daily dose AKB-6548 .</brief_summary>
	<brief_title>Effect AKB-6548 Pharmacokinetics Celecoxib</brief_title>
	<detailed_description>To assess single dose plasma pharmacokinetics ( PK ) , safety , tolerability celecoxib healthy subject CYP2C9 extensive metabolizer ( EM ) genotype administer alone follow multiple daily dose AKB-6548 .</detailed_description>
	<mesh_term>Celecoxib</mesh_term>
	<criteria>Healthy male subject 18 55 year age , inclusive , body mass index 18 30 kg/sq.meters , inclusive . Subjects follow genotype base upon pharmacogenetic test result : CYP2C9 EM : *1*1 . Current past history cardiovascular , cerebrovascular , pulmonary , renal liver disease . Positive serology result HBsAg , HCV , HIV Screening . Significant renal impairment evidence estimate glomerular filtration rate ( eGFR ) &lt; 65 mL/minute/1.73 sq.meters . Known hypersensitivity celecoxib sulfonamide . History asthma , urticaria , allergictype reaction take aspirin NSAIDs . Known active cancer history chemotherapy use within previous 24 month . Current past history gastric duodenal ulcer diseases GI tract ( include gastric bypass surgery ) could interfere absorption study drug . Current past history gastrointestinal bleeding . Any history alcohol drug abuse within previous year prior Screening . Subjects know history smoking and/or use nicotine nicotine containing product within past 6 month .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>October 2015</verification_date>
</DOC>